Histiocytosis


Acknowledgment

The authors would like to acknowledge the contribution of Drs. Jeremy Gibson and Meenakshi Dogra to this text in the previous edition.

Risk

  • LCH is the most commonly known form.

  • Incidence: 1:250,000 in children, with about a third of this incidence in adults.

  • Seen in all ages, but peak incidence is at 0–3 y of age.

  • Male:female ratio: 1.5:1.

  • Sporadic development with no established genetic predisposition.

Perioperative Risks

  • Dependent on organ systems involved and extent of dysfunction

Worry About

  • Specific organ dysfunction caused by infiltration with histiocytes, including liver, lungs, hematopoietic system, pituitary, spleen, and bone

  • Can involve single or multiple sites and organs

  • Treated with steroids and chemotherapy, which may cause adrenal insufficiency and result in the pt requiring stress steroids in the periop period

  • Central diabetes insipidus due to posterior pituitary involvement

  • Cervical instability if lesions present in cervical vertebrae

  • Severe pulm dysfunction possible; pulm Htn without overt right heart failure

Overview

  • A broad group of disorders involving infiltration of affected organs with monocytes, macrophages, and dendritic cells.

  • The most commonly discussed disorder is LCH, previously known separately as eosinophilic granuloma, Hand-Schüller-Christian disease, and Letterer-Siwe disease.

  • Severity of clinical symptoms varies markedly and can involve primarily skin and/or bone or liver, lung, or brain.

  • Can be limited or progressive and fatal. Younger children with multiple or severe organ involvement of “risk organs” (liver, lungs, spleen, hematopoietic system) have a high mortality.

  • Usual clinical presentation is in the first decade of life.

  • Pathophysiology is unclear and treatment is nonspecific.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here